2024-05-15
#reports #VRME
[VerifyMe](https://eninvs.com/all.php?name=VRME) (Security and Protection Services) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=VRME&q=2024 q1&id=781855)
(2024-05-14, Before Market Open):
- Revenue 0.0% YoY (vs -10.0% in previous quarter and historical rate +69.6%)
- EBITDA 0.0% YoY (vs -14.3% in previous quarter)
- EBITDA margin 50.0% has not changed compared to 50.0% same period last year
- EV/Sales multiple is 0.7x
------------------------------------------------
2024-05-15
#reports #UNB
[Union Bankshares](https://eninvs.com/all.php?name=UNB) (Banks — Regional) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169477)
(2024-04-17, After Market Close):
- Revenue -10.0% YoY (vs -10.0% in previous quarter and historical rate -8.3%)
- Net Income -33.3% YoY (vs +500.0% in previous quarter and historical rate -3.3%)
- Net Income margin 22.2% decreased compared to 30.0% same period last year
- P/E multiple is 10.5x compared to historical level (75th percentile) of 24.8x
- P/S multiple is 3.1x
- Price to book: 1.8x
The company showed EPS +$0.53 per share. At the opening of the session the share price went up +0.1% vs S&P500 +0.2%
------------------------------------------------
2024-05-15
#reports #TISI
[Team](https://eninvs.com/all.php?name=TISI) (Specialty Business Services) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169476)
(2023-05-11, After Market Close):
- Revenue -1.0% YoY (vs +1.4% in previous quarter and historical rate +2.4%)
- Net Income margin -8.5% increased compared to -12.4% same period last year
- P/S multiple is 0.0x
- Price to book: 0.6x
At the opening of the session the share price went down -0.2% vs S&P500 +0.2%
------------------------------------------------
2024-05-15
#reports #STRS
[Stratus Properties](https://eninvs.com/all.php?name=STRS) (Real Estate — Diversified) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169472)
(2024-05-13, Before Market Open):
- Revenue +150.0% YoY (vs -69.2% in previous quarter and historical rate +7.8%)
- EBITDA margin 106.7% increased compared to -83.3% same period last year
- EV/EBITDA multiple is 45.1x compared to historical level (75th percentile) of 81.6x
- EV/Sales multiple is 15.0x
The company showed EPS +$0.56 per share. At the opening of the session the share price went down -4.7% vs S&P500 +0.2%
------------------------------------------------
2024-05-15
#reports #SSTI
[ShotSpotter](https://eninvs.com/all.php?name=SSTI) (Software — Application) reported for 2024 q1
(2024-05-14, After Market Close):
- Revenue +19.0% YoY (vs -67.9% in previous quarter and historical rate +30.7%)
- Net Debt decreased by $3.0 mln over the past reporting period (1.7% of market cap)
- FCF (LTM) -$0.0 bln (negative), 3.4% of market cap
- EV/EBITDA multiple is 24.8x compared to historical level (75th percentile) of 67.6x
- EV/Sales multiple is 1.8x
------------------------------------------------
2024-05-15
#reports #PXLW
[Pixelworks](https://eninvs.com/all.php?name=PXLW) (Semiconductors) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=PXLW&q=2024 q1&id=781900)
(2024-05-14, After Market Close):
- Revenue +60.0% YoY (vs +17.6% in previous quarter and historical rate +29.7%)
- EBITDA margin -25.0% increased compared to -90.0% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (0.9% of market cap)
- FCF (LTM) -$0.0 bln (negative), 11.3% of market cap
- EV/Sales multiple is 1.7x
------------------------------------------------
2024-05-15
#reports #PRPO
[Precipio](https://eninvs.com/all.php?name=PRPO) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169505)
(2023-11-13, After Market Close):
- Revenue 0.0% YoY (vs +33.3% in previous quarter and historical rate +48.6%)
- EBITDA margin -33.3% increased compared to -66.7% same period last year
- EV/Sales multiple is 9.9x
At the opening of the session the share price went down -7.1% vs S&P500 +1.0%
------------------------------------------------
2024-05-15
#reports #POAI
[Predictive Oncology](https://eninvs.com/all.php?name=POAI) (Medical Instruments and Supplies) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169528)
(2023-05-17, After Market Close):
- Revenue +75.0% YoY (vs -7.7% in previous quarter and historical rate +79.7%)
- EBITDA margin -970.0% decreased compared to -22.5% same period last year
- Net Debt increased by $3.4 bln over the past reporting period (2709.1% of market cap)
- FCF (LTM) -$13.7 bln (negative), 10817.5% of market cap
- EV/EBITDA multiple is 0.3x compared to historical level (75th percentile) of 1.5x
- EV/Sales multiple is -2.3x
------------------------------------------------
2024-05-15
#reports #PMD
[Psychemedics Corporation](https://eninvs.com/all.php?name=PMD) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169480)
(2024-05-13, Before Market Open):
- Revenue -16.7% YoY (vs -16.7% in previous quarter and historical rate +9.8%)
- EBITDA margin -20.0% decreased compared to -16.7% same period last year
- Net Debt decreased by $1.0 mln over the past reporting period (6.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 6.8% of market cap
- EV/Sales multiple is 0.7x
------------------------------------------------
2024-05-15
#reports #PBH
[Prestige Consumer Healthcare](https://eninvs.com/all.php?name=PBH) (Medicines manufacturer) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=PBH&q=2024 q1&id=781897)
(2024-05-14, After Market Close):
- Revenue -3.1% YoY (vs +2.5% in previous quarter and historical rate +6.3%)
- EBITDA margin 32.5% increased compared to -95.5% same period last year
- Net Debt decreased by $56.0 mln over the past reporting period (1.6% of market cap)
- FCF (LTM) +$0.2 bln (positive), 5.2% of market cap
- EV/EBITDA multiple is 12.5x compared to historical level (75th percentile) of 466.6x
- EV/Sales multiple is 4.1x
On post-market the stock shows a decrease by -7.7%
------------------------------------------------
2024-05-15
#reports #OVLY
[Oak Valley Bancorp](https://eninvs.com/all.php?name=OVLY) (Banks — Regional) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169531)
(2024-04-18, Before Market Open):
- Revenue -15.0% YoY (vs -15.0% in previous quarter and historical rate +14.8%)
- Net Income -41.7% YoY (vs -33.3% in previous quarter and historical rate +46.6%)
- Net Income margin 41.2% decreased compared to 60.0% same period last year
- P/E multiple is 5.6x compared to historical level (75th percentile) of 8.2x
- P/S multiple is 2.8x
- Price to book: 1.2x
The company showed EPS +$0.69 per share. At the opening of the session the share price went up +0.3% vs S&P500 +0.2%
------------------------------------------------
2024-05-15
#reports #NSYS
[Nortech Systems](https://eninvs.com/all.php?name=NSYS) (Electronic Components) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169412)
(2024-05-16, After Market Close):
- Revenue -2.9% YoY (vs 0.0% in previous quarter and historical rate +13.0%)
- EBITDA 0.0% YoY (vs -62.5% in previous quarter and historical rate +49.0%)
- EBITDA margin 5.9% increased compared to 5.7% same period last year
- Net Debt decreased by $2.0 mln over the past reporting period (4.8% of market cap)
- FCF (LTM) +$0.0 bln (positive), 4.8% of market cap
- EV/EBITDA multiple is 5.9x compared to historical level (75th percentile) of 4.8x
- EV/Sales multiple is 0.4x
The company showed EPS +$2942.31 per share
------------------------------------------------
2024-05-15
#reports #NAII
[Natural Alternatives International](https://eninvs.com/all.php?name=NAII) (Packaged Foods) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169479)
(2024-05-13, After Market Close):
- Revenue -24.2% YoY (vs -40.5% in previous quarter and historical rate +6.5%)
- EBITDA margin -4.0% increased compared to -6.1% same period last year
- Net Debt increased by $2.0 mln over the past reporting period (5.3% of market cap)
- FCF (LTM) -$0.0 bln (negative), 44.7% of market cap
- EV/EBITDA multiple is 10.1x compared to historical level (75th percentile) of 4.9x
- EV/Sales multiple is 0.4x
------------------------------------------------
2024-05-15
#reports #MTEX
[Mannatech](https://eninvs.com/all.php?name=MTEX) (Household and Personal Products) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169389)
(2024-05-13, Before Market Open):
- Revenue -14.7% YoY (vs -2.9% in previous quarter and historical rate -0.2%)
- EBITDA margin 3.4% increased compared to 2.9% same period last year
- EV/EBITDA multiple is 1.7x compared to historical level (75th percentile) of 2.8x
- EV/Sales multiple is 0.1x
At the opening of the session the share price went down -7.4% vs S&P500 +0.2%
------------------------------------------------
2024-05-15
#reports #IRIX
[IRIDEX Corporation](https://eninvs.com/all.php?name=IRIX) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=IRIX&q=2024 q1&id=781891)
(2024-05-14, After Market Close):
- Revenue -14.3% YoY (vs -20.0% in previous quarter and historical rate +10.9%)
- EBITDA margin -25.0% decreased compared to -14.3% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (2.0% of market cap)
- FCF (LTM) -$0.0 bln (negative), 12.0% of market cap
- EV/Sales multiple is 0.9x
------------------------------------------------
2024-05-15
#reports #INTZ
[Intrusion](https://eninvs.com/all.php?name=INTZ) (Software — Infrastructure) reported for 2024 q1
(2024-05-15, After Market Close):
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate -16.7%)
- EBITDA margin -200.0% increased compared to -400.0% same period last year
- EV/Sales multiple is 4.3x
------------------------------------------------
2024-05-15
#reports #DMTK
[DermTech](https://eninvs.com/all.php?name=DMTK) (Medicine services provider) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=DMTK&q=2024 q1&id=781886)
(2024-05-14, After Market Close):
- Revenue +33.3% YoY (vs +33.3% in previous quarter and historical rate +54.9%)
- EBITDA margin -475.0% increased compared to -1033.3% same period last year
- Net Debt increased by $16.0 mln over the past reporting period (72.3% of market cap)
- FCF (LTM) -$0.0 bln (negative), 216.8% of market cap
- EV/Sales multiple is 2.3x
------------------------------------------------
2024-05-15
#reports #DCTH
[Delcath Systems](https://eninvs.com/all.php?name=DCTH) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=DCTH&q=2024 q1&id=781831)
(2024-05-14, Before Market Open):
- Revenue +200.0% YoY (vs 0.0% in previous quarter and historical rate +62.5%)
- EBITDA margin -333.3% increased compared to -800.0% same period last year
- Net Debt increased by $7.0 mln over the past reporting period (4.0% of market cap)
- FCF (LTM) +$0.0 bln (positive), 4.5% of market cap
- EV/Sales multiple is 40.2x
At the opening of the session the share price went up +11.3% vs S&P500 0.0%
------------------------------------------------
2024-05-15
#reports #BLIN
[Bridgeline Digital](https://eninvs.com/all.php?name=BLIN) (Software — Infrastructure) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=BLIN&q=2024 q1&id=781878)
(2024-05-14, After Market Close):
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate +19.4%)
- EV/Sales multiple is 0.6x
------------------------------------------------
2024-05-15
#reports #ACOR
[Acorda Therapeutics](https://eninvs.com/all.php?name=ACOR) (Drug Manufacturers — Specialty and Generic) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169502)
(2023-08-08, After Market Close):
- Revenue -9.1% YoY (vs +22.6% in previous quarter and historical rate -7.7%)
- EBITDA margin -95.0% decreased compared to -13.6% same period last year
- Net Debt increased by $26.0 mln over the past reporting period (161.6% of market cap)
- FCF (LTM) -$0.0 bln (negative), 248.6% of market cap
- EV/Sales multiple is 1.8x
At the opening of the session the share price went down -2.2% vs S&P500 0.0%
------------------------------------------------
2024-05-15
#reports #AC
[Associated Capital Group](https://eninvs.com/all.php?name=AC) (Capital Markets) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=AC&q=2024 q1&id=780759)
(2024-05-09, After Market Close):
- Revenue +50.0% YoY (vs -25.0% in previous quarter and historical rate +1.3%)
- Net Income -22.2% YoY (vs +14.3% in previous quarter and historical rate -23.9%)
- Net Income margin 466.7% decreased compared to 900.0% same period last year
- P/E multiple is 25.2x compared to historical level (75th percentile) of 24.0x
- P/S multiple is 56.2x
- Price to book: 0.8x
The company showed EPS +$0.64 per share. At the opening of the session the share price went down -0.3% vs S&P500 +0.2%
------------------------------------------------
2024-05-15
#reports #ABSI
[Absci Corporation](https://eninvs.com/all.php?name=ABSI) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169374)
(2024-05-14, Before Market Open):
- EBITDA margin 6800.0% increased compared to -2100.0% same period last year
- Net Debt decreased by $65.0 mln over the past reporting period (13.5% of market cap)
- FCF (LTM) -$0.0 bln (negative), 8.5% of market cap
- EV/Sales multiple is 83.3x
At the opening of the session the share price went down -9.1% vs S&P500 0.0%
------------------------------------------------
2024-05-15
#reports #SE
@ gaming
[Sea](https://eninvs.com/all.php?name=SE) (Electronic Gaming and Multimedia) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=SE&q=2024 q1&id=781851)
(2024-05-14, Before Market Open):
- Revenue +22.8% YoY (vs +4.8% in previous quarter and historical rate +45.5%)
- EBITDA -29.8% YoY (vs -122.8% in previous quarter and historical rate +37.3%)
- EBITDA margin 3.4% decreased compared to 6.0% same period last year
- Net Debt decreased by $213.0 mln over the past reporting period (0.6% of market cap)
- FCF (LTM) -$1.0 bln (negative), 2.8% of market cap
- EV/EBITDA multiple is 121.6x compared to historical level (75th percentile) of 82.6x
- EV/Sales multiple is 2.6x
------------------------------------------------
2024-05-15
#reports #BABA
@ china , @ e-commerce
[Alibaba](https://eninvs.com/all.php?name=BABA) (Chinese e-commerce giant) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=BABA&q=2024 q1&id=781826)
(2024-05-14, Before Market Open):
- Revenue +1.4% YoY (vs +2.1% in previous quarter and historical rate +8.4%)
- EBITDA -8.2% YoY (vs -25.4% in previous quarter and historical rate +13.8%)
- EBITDA margin 10.8% decreased compared to 11.9% same period last year
- Net Debt increased by $6.6 bln over the past reporting period (3.2% of market cap)
- FCF (LTM) -$3.7 bln (negative), 1.8% of market cap
- EV/EBITDA multiple is 8.2x compared to historical level (75th percentile) of 14.7x
- EV/Sales multiple is 1.3x
At the opening of the session the share price went down -5.9% vs S&P500 0.0%
------------------------------------------------
2024-05-14
#reports #OPTN
[OptiNose](https://eninvs.com/all.php?name=OPTN) (Drug Manufacturers — Specialty and Generic) reported for 2024 q1
(2024-05-14, Before Market Open):
- Revenue +25.0% YoY (vs -4.8% in previous quarter and historical rate +28.3%)
- EBITDA margin -53.3% increased compared to -116.7% same period last year
- Net Debt increased by $22.0 mln over the past reporting period (16.7% of market cap)
- FCF (LTM) -$0.0 bln (negative), 8.4% of market cap
- EV/Sales multiple is 2.0x
At the opening of the session the share price went down -5.1% vs S&P500 0.0%
------------------------------------------------
2024-05-14
#reports #HYFM
[Hydrofarm Holdings Group, Inc.](https://eninvs.com/all.php?name=HYFM) (Farm and Heavy Construction Machinery) reported for 2024 q1
(2024-05-14, Before Market Open):
- Revenue -12.9% YoY (vs -23.0% in previous quarter and historical rate -18.2%)
- EBITDA +133.3% YoY (vs +1500.0% in previous quarter and historical rate +5.6%)
- EBITDA margin 13.0% increased compared to 4.8% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (2.4% of market cap)
- FCF (LTM) +$0.0 bln (positive), 45.1% of market cap
- EV/EBITDA multiple is 18.0x compared to historical level (75th percentile) of 185.1x
- EV/Sales multiple is 0.9x
At the opening of the session the share price went up +2.1% vs S&P500 0.0%
------------------------------------------------
2024-05-14
#reports #GRNQ
[Greenpro Capital](https://eninvs.com/all.php?name=GRNQ) (Consulting Services) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169352)
(2022-05-10):
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate +50.0%)
- Net Debt increased by $1.0 mln over the past reporting period (10.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 10.8% of market cap
- EV/Sales multiple is 2.1x
The company showed EPS -$0.04 per share
------------------------------------------------
2024-05-14
#reports #DTIL
[Precision BioSciences](https://eninvs.com/all.php?name=DTIL) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169340)
(2024-05-08, Before Market Open):
- Revenue +100.0% YoY (vs -72.0% in previous quarter and historical rate +63.4%)
- EBITDA margin -77.8% increased compared to -255.6% same period last year
- Net Debt decreased by $21.0 mln over the past reporting period (1.6% of market cap)
- FCF (LTM) -$0.0 bln (negative), 3.2% of market cap
- EV/Sales multiple is 20.5x
The company showed EPS +$0.00 per share. At the opening of the session the share price went up +4.5% vs S&P500 -0.4%
------------------------------------------------
2024-05-14
#reports #CAAS
[China Automotive Systems](https://eninvs.com/all.php?name=CAAS) (Auto Parts) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169368)
(2024-05-14, Before Market Open):
- Revenue -2.1% YoY (vs +23.3% in previous quarter and historical rate +25.4%)
- EBITDA +15.4% YoY (vs +280.0% in previous quarter and historical rate +71.5%)
- EBITDA margin 10.8% increased compared to 9.2% same period last year
- Net Debt increased by $55.0 mln over the past reporting period (53.1% of market cap)
- FCF (LTM) +$0.0 bln (positive), 18.4% of market cap
- EV/EBITDA multiple is 0.8x compared to historical level (75th percentile) of 3.7x
- EV/Sales multiple is 0.1x
At the opening of the session the share price went up +3.5% vs S&P500 0.0%
------------------------------------------------
2024-05-14
#reports #BIOL
[BIOLASE](https://eninvs.com/all.php?name=BIOL) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169325)
(2023-11-09, After Market Close):
- Revenue 0.0% YoY (vs -7.1% in previous quarter and historical rate +31.0%)
- EBITDA margin -40.0% increased compared to -50.0% same period last year
- Net Debt increased by $2.0 mln over the past reporting period (2028.6% of market cap)
- FCF (LTM) +$0.0 bln (positive), 5071.5% of market cap
- EV/Sales multiple is 1.0x
At the opening of the session the share price went down -23.8% vs S&P500 -0.5%
------------------------------------------------
2024-05-14
#reports #ASRV
[AmeriServ Financial](https://eninvs.com/all.php?name=ASRV) (Banks — Regional) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169330)
(2024-04-16, Before Market Open):
- Revenue -10.0% YoY (vs -10.0% in previous quarter and historical rate -11.5%)
- Net Income 0.0% YoY (vs -600.0% in previous quarter and historical rate +5.4%)
- Net Income margin 22.2% increased compared to 20.0% same period last year
- P/S multiple is 1.3x
- Price to book: 0.4x
The company showed EPS +$0.11 per share. At the opening of the session the share price went up +3.5% vs S&P500 +0.1%
------------------------------------------------
2024-05-14
#reports #GEO
@ REITs
[The GEO Group](https://eninvs.com/all.php?name=GEO) (REIT — Healthcare Facilities) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169256)
(2024-05-07, Before Market Open):
- Revenue -0.3% YoY (vs -2.1% in previous quarter and historical rate +1.4%)
- EBITDA -11.2% YoY (vs -17.9% in previous quarter and historical rate +5.9%)
- EBITDA margin 18.3% decreased compared to 20.6% same period last year
- Net Debt decreased by $58.0 mln over the past reporting period (3.6% of market cap)
- FCF (LTM) +$0.1 bln (positive), 7.2% of market cap
- EV/EBITDA multiple is 7.0x compared to historical level (75th percentile) of 7.3x
- EV/Sales multiple is 1.4x
The company showed EPS +$0.14 per share. At the opening of the session the share price went down -5.3% vs S&P500 +0.1%
------------------------------------------------
2024-05-14
#reports #XGN
[Exagen](https://eninvs.com/all.php?name=XGN) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169273)
(2024-05-13, Before Market Open):
- Revenue +27.3% YoY (vs +7.7% in previous quarter and historical rate +11.1%)
- EBITDA margin -21.4% increased compared to -63.6% same period last year
- Net Debt increased by $9.0 mln over the past reporting period (32.1% of market cap)
- FCF (LTM) -$0.0 bln (negative), 50.0% of market cap
- EV/Sales multiple is 0.4x
The company showed EPS -$0.19 per share. At the opening of the session the share price went up +0.6% vs S&P500 +0.2%
------------------------------------------------
2024-05-14
#reports #VNRX
[VolitionRx Limited](https://eninvs.com/all.php?name=VNRX) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169295)
(2024-05-13, After Market Close):
- Revenue +14.7% YoY (vs +103.3% in previous quarter and historical rate +109.8%)
- EBITDA margin -4721.5% increased compared to -5848.7% same period last year
- Net Debt increased by $8.6 bln over the past reporting period (17626.1% of market cap)
- FCF (LTM) +$1.1 bln (positive), 2287.4% of market cap
- EV/EBITDA multiple is 0.2x compared to historical level (75th percentile) of 0.5x
- EV/Sales multiple is -8.8x
------------------------------------------------
2024-05-14
#reports #URGN
[UroGen Pharma](https://eninvs.com/all.php?name=URGN) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169272)
(2024-05-13, Before Market Open):
- Revenue +11.8% YoY (vs +33.3% in previous quarter and historical rate +67.5%)
- EBITDA margin -136.8% increased compared to -158.8% same period last year
- Net Debt decreased by $28.0 mln over the past reporting period (6.4% of market cap)
- FCF (LTM) -$0.1 bln (negative), 22.7% of market cap
- EV/Sales multiple is 4.4x
At the opening of the session the share price went down -14.4% vs S&P500 +0.2%
------------------------------------------------
2024-05-14
#reports #TKNO
[Alpha Teknova, Inc.](https://eninvs.com/all.php?name=TKNO) (Drug Manufacturers — Specialty and Generic) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169293)
(2024-05-13, After Market Close):
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate +3.2%)
- EBITDA margin -77.8% increased compared to -88.9% same period last year
- Net Debt increased by $8.0 mln over the past reporting period (16.4% of market cap)
- FCF (LTM) +$0.0 bln (positive), 2.0% of market cap
- EV/Sales multiple is 1.6x
------------------------------------------------
2024-05-14
#reports #TBPH
[Theravance Biopharma](https://eninvs.com/all.php?name=TBPH) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=TBPH&q=2024 q1&id=781653)
(2024-05-13, After Market Close):
- Revenue -68.1% YoY (vs +20.0% in previous quarter and historical rate +23.9%)
- EBITDA margin -73.3% decreased compared to -53.2% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (0.1% of market cap)
- FCF (LTM) -$0.1 bln (negative), 20.1% of market cap
- EV/EBITDA multiple is 23.2x compared to historical level (75th percentile) of 1074.0x
- EV/Sales multiple is 6.2x
------------------------------------------------
2024-05-14
#reports #STXS
[Stereotaxis](https://eninvs.com/all.php?name=STXS) (Medical Instruments and Supplies) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=STXS&q=2024 q1&id=781651)
(2024-05-13, After Market Close):
- Revenue 0.0% YoY (vs -28.6% in previous quarter and historical rate +1.7%)
- EBITDA margin -71.4% increased compared to -85.7% same period last year
- Net Debt increased by $22.0 mln over the past reporting period (12.3% of market cap)
- FCF (LTM) -$0.0 bln (negative), 3.9% of market cap
- EV/Sales multiple is 6.1x
On post-market the stock shows a growth by +6.5%
------------------------------------------------
2024-05-14
#reports #SND
[Smart Sand](https://eninvs.com/all.php?name=SND) (Oil and Gas Equipment and Services) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169291)
(2024-05-13, After Market Close):
- Revenue +1.2% YoY (vs -16.2% in previous quarter and historical rate +50.7%)
- EBITDA margin 1.2% increased compared to -1.2% same period last year
- Net Debt decreased by $38.0 mln over the past reporting period (42.4% of market cap)
- FCF (LTM) -$0.0 bln (negative), 4.5% of market cap
- EV/EBITDA multiple is 31.9x compared to historical level (75th percentile) of 21.3x
- EV/Sales multiple is 0.4x
------------------------------------------------
2024-05-14
#reports #SENS
[Senseonics](https://eninvs.com/all.php?name=SENS) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169289)
(2024-05-13, After Market Close):
- Revenue +25.0% YoY (vs +33.3% in previous quarter and historical rate +54.4%)
- EBITDA -120.9% YoY (vs -45.9% in previous quarter and historical rate +20.6%)
- EBITDA margin -360.0% decreased compared to 2150.0% same period last year
- Net Debt increased by $6.0 mln over the past reporting period (2.4% of market cap)
- FCF (LTM) -$0.0 bln (negative), 10.7% of market cap
- EV/Sales multiple is 10.6x
------------------------------------------------
2024-05-14
#reports #QUIK
[QuickLogic Corporation](https://eninvs.com/all.php?name=QUIK) (Semiconductors) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=QUIK&q=2024 q1&id=781646)
(2024-05-13, After Market Close):
- Revenue +50.0% YoY (vs +75.0% in previous quarter and historical rate +37.9%)
- Net Debt decreased by $6.0 mln over the past reporting period (3.4% of market cap)
- EV/EBITDA multiple is 56.0x compared to historical level (75th percentile) of 112.0x
- EV/Sales multiple is 7.3x
------------------------------------------------
2024-05-14
#reports #NSPR
[InspireMD](https://eninvs.com/all.php?name=NSPR) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169298)
(2024-05-14, Before Market Open):
- Revenue +100.0% YoY (vs +100.0% in previous quarter and historical rate +66.7%)
- EBITDA margin -350.0% increased compared to -400.0% same period last year
- Net Debt increased by $5.0 mln over the past reporting period (26.6% of market cap)
- FCF (LTM) +$0.0 bln (positive), 159.5% of market cap
- EV/EBITDA multiple is 0.6x compared to historical level (75th percentile) of 1.0x
- EV/Sales multiple is -1.8x
------------------------------------------------
2024-05-14
#reports #LIVE
[Live Ventures](https://eninvs.com/all.php?name=LIVE) (Specialty Retail) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=LIVE&q=2024 q1&id=645304)
(2023-05-11, Before Market Open):
- Revenue +30.8% YoY (vs +71.0% in previous quarter and historical rate +56.2%)
- EBITDA -66.7% YoY (vs -28.6% in previous quarter and historical rate +2.8%)
- EBITDA margin 2.5% decreased compared to 9.9% same period last year
- Net Debt increased by $8.0 mln over the past reporting period (9.9% of market cap)
- FCF (LTM) -$0.0 bln (negative), 59.2% of market cap
- EV/EBITDA multiple is 13.0x compared to historical level (75th percentile) of 9.7x
- EV/Sales multiple is 0.7x
At the opening of the session the share price went down -4.0% vs S&P500 -0.1%
------------------------------------------------
2024-05-14
#reports #KFFB
[Kentucky First Federal Bancorp](https://eninvs.com/all.php?name=KFFB) (Banks — Regional) reported for 2024 q1
(2024-05-13, After Market Close):
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate -6.9%)
- P/E multiple is 28.8x compared to historical level (75th percentile) of 49.0x
- P/S multiple is 3.6x
- Price to book: 0.6x
------------------------------------------------
2024-05-14
#reports #IDN
[Intellicheck](https://eninvs.com/all.php?name=IDN) (Software — Application) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=IDN&q=2024 q1&id=781641)
(2024-05-13, After Market Close):
- Revenue +25.0% YoY (vs 0.0% in previous quarter and historical rate +28.6%)
- EV/Sales multiple is 2.3x
------------------------------------------------
2024-05-14
#reports #DIS
[Walt Disney](https://eninvs.com/all.php?name=DIS) (Entertainment media conglomerate) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=161905)
(2024-02-07, After Market Close):
- Revenue +1.2% YoY (vs +0.2% in previous quarter and historical rate +16.2%)
- EBITDA -39.7% YoY (vs +17.7% in previous quarter and historical rate +26.2%)
- EBITDA margin 9.4% decreased compared to 15.7% same period last year
- Net Debt decreased by $1.1 bln over the past reporting period (0.6% of market cap)
- FCF (LTM) +$6.5 bln (positive), 3.3% of market cap
- EV/EBITDA multiple is 24.0x compared to historical level (75th percentile) of 33.8x
- EV/Sales multiple is 2.7x
The company showed EPS +$1.04 per share. At the opening of the session the share price went up +8.0% vs S&P500 0.0%
------------------------------------------------
2024-05-14
#reports #DERM
[Journey Medical Corporation](https://eninvs.com/all.php?name=DERM) (Drug Manufacturers — Specialty and Generic) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=DERM&q=2024 q1&id=781638)
(2024-05-13, After Market Close):
- Revenue +8.3% YoY (vs -6.3% in previous quarter and historical rate +0.5%)
- EBITDA margin -84.6% decreased compared to -83.3% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (1.5% of market cap)
- FCF (LTM) +$0.0 bln (positive), 22.8% of market cap
- EV/Sales multiple is 0.7x
------------------------------------------------
2024-05-14
#reports #CARA
[Cara Therapeutics](https://eninvs.com/all.php?name=CARA) (Medicines Developer) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169279)
(2024-05-13, After Market Close):
- Revenue -66.7% YoY (vs 0.0% in previous quarter and historical rate +21.4%)
- EBITDA margin -1500.0% decreased compared to -450.0% same period last year
- Net Debt increased by $30.0 mln over the past reporting period (74.4% of market cap)
- FCF (LTM) -$0.1 bln (negative), 124.0% of market cap
- EV/EBITDA multiple is 0.2x compared to historical level (75th percentile) of 0.4x
- EV/Sales multiple is -1.3x
------------------------------------------------
2024-05-14
#reports #AP
[Ampco-Pittsburgh Corporation](https://eninvs.com/all.php?name=AP) (Metal Fabrication) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169277)
(2024-05-13, After Market Close):
- Revenue +4.8% YoY (vs +14.9% in previous quarter and historical rate +9.9%)
- EBITDA -16.7% YoY (vs -1950.0% in previous quarter and historical rate +33.5%)
- EBITDA margin 4.5% decreased compared to 5.7% same period last year
- Net Debt decreased by $1.0 mln over the past reporting period (2.7% of market cap)
- FCF (LTM) -$0.0 bln (negative), 21.7% of market cap
- EV/EBITDA multiple is 2.8x compared to historical level (75th percentile) of 18.9x
- EV/Sales multiple is 0.4x
------------------------------------------------
2024-05-14
#reports #AKYA
[Akoya Biosciences, Inc.](https://eninvs.com/all.php?name=AKYA) (Medical Instruments and Supplies) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=AKYA&q=2024 q1&id=781630)
(2024-05-13, After Market Close):
- Revenue -14.3% YoY (vs +23.8% in previous quarter and historical rate +24.7%)
- EBITDA margin -105.6% decreased compared to -71.4% same period last year
- Net Debt increased by $21.0 mln over the past reporting period (10.4% of market cap)
- FCF (LTM) -$0.0 bln (negative), 7.9% of market cap
- EV/Sales multiple is 2.4x
------------------------------------------------
2024-05-14
#reports #AGYS
[Agilysys](https://eninvs.com/all.php?name=AGYS) (Software — Application) reported for 2024 q1
(2024-05-13, After Market Close):
- Revenue +17.0% YoY (vs +22.0% in previous quarter and historical rate +20.6%)
- EBITDA 0.0% YoY (vs +100.0% in previous quarter)
- EBITDA margin 6.5% decreased compared to 7.5% same period last year
- Net Debt decreased by $29.0 mln over the past reporting period (1.3% of market cap)
- FCF (LTM) +$0.1 bln (positive), 2.8% of market cap
- EV/EBITDA multiple is 119.9x compared to historical level (75th percentile) of 137.3x
- EV/Sales multiple is 8.6x
------------------------------------------------
2024-05-14
#reports #TSLA
@ artificial-intelligence , @ electric-vehicles
[Tesla](https://eninvs.com/all.php?name=TSLA) (Vehicles manufacturer) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=162090)
(2024-01-24, After Market Close):
- Revenue -8.7% YoY (vs +3.5% in previous quarter and historical rate +42.5%)
- EBITDA -34.9% YoY (vs -30.1% in previous quarter and historical rate +56.2%)
- EBITDA margin 11.3% decreased compared to 15.9% same period last year
- Net Debt increased by $22.9 bln over the past reporting period (4.2% of market cap)
- FCF (LTM) +$4.3 bln (positive), 0.8% of market cap
- EV/EBITDA multiple is 42.4x compared to historical level (75th percentile) of 98.2x
- EV/Sales multiple is 5.5x
The company showed EPS +$2.27 per share. At the opening of the session the share price went down -8.7% vs S&P500 +0.2%
------------------------------------------------
2024-05-14
#reports #HUYA
@ china , @ gaming
[HUYA](https://eninvs.com/all.php?name=HUYA) (Entertainment) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=HUYA&q=2024 q1&id=781612)
(2024-03-19, Before Market Open):
- Revenue -26.8% YoY (vs -29.5% in previous quarter and historical rate -17.1%)
- EBITDA +27.3% YoY (vs -3200.0% in previous quarter and historical rate +13.9%)
- EBITDA margin 6.7% increased compared to 3.9% same period last year
- Net Debt increased by $43.0 mln over the past reporting period (3.8% of market cap)
- FCF (LTM) -$0.4 bln (negative), 38.6% of market cap
- EV/EBITDA multiple is 3.5x compared to historical level (75th percentile) of 155.0x
- EV/Sales multiple is 0.2x
At the opening of the session the share price went down -8.9% vs S&P500 -0.2%
------------------------------------------------
2024-05-13
#reports #XPER
[Xperi](https://eninvs.com/all.php?name=XPER) (Semiconductor Equipment and Materials) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=168842)
(2024-05-08, After Market Close):
- Revenue -6.3% YoY (vs +0.7% in previous quarter and historical rate -11.8%)
- EBITDA margin -24.4% decreased compared to -23.6% same period last year
- Net Debt increased by $43.0 mln over the past reporting period (10.2% of market cap)
- FCF (LTM) +$0.0 bln (positive), 9.5% of market cap
- EV/Sales multiple is 0.7x
The company showed EPS +$0.01 per share. At the opening of the session the share price went down -5.2% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #VZIO
[VIZIO Holding Corp.](https://eninvs.com/all.php?name=VZIO) (Consumer Electronics) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=VZIO&q=2024 q1&id=780535)
(2024-05-08, After Market Close):
- Revenue -0.8% YoY (vs -5.8% in previous quarter and historical rate -9.1%)
- EBITDA margin -5.4% decreased compared to -0.6% same period last year
- Net Debt increased by $18.0 mln over the past reporting period (0.9% of market cap)
- FCF (LTM) +$0.0 bln (positive), 0.2% of market cap
- EV/EBITDA multiple is 169.8x compared to historical level (75th percentile) of 65.8x
- EV/Sales multiple is 1.0x
The company showed EPS -$0.06 per share. At the opening of the session the share price went down -1.5% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #USPH
[U.S. Physical Therapy](https://eninvs.com/all.php?name=USPH) (Medical services provider) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169238)
(2024-05-07, After Market Close):
- Revenue +4.7% YoY (vs +9.9% in previous quarter and historical rate +14.2%)
- EBITDA -14.3% YoY (vs -72.7% in previous quarter and historical rate -3.2%)
- EBITDA margin 11.5% decreased compared to 14.1% same period last year
- Net Debt decreased by $1.8 bln over the past reporting period (127.1% of market cap)
- FCF (LTM) -$0.1 bln (negative), 9.8% of market cap
- EV/EBITDA multiple is 48.4x compared to historical level (75th percentile) of 45.3x
- EV/Sales multiple is 5.1x
The company showed EPS +$0.46 per share. At the opening of the session the share price went down -2.8% vs S&P500 -0.4%
------------------------------------------------
2024-05-13
#reports #SUPN
[Supernus Pharmaceuticals](https://eninvs.com/all.php?name=SUPN) (Pharmaceutical manufacturer) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=SUPN&q=2024 q1&id=780506)
(2024-05-08, After Market Close):
- Revenue -6.5% YoY (vs -1.8% in previous quarter and historical rate +3.2%)
- EBITDA -19.5% YoY (vs -57.1% in previous quarter and historical rate -9.6%)
- EBITDA margin 22.9% decreased compared to 26.6% same period last year
- Net Debt decreased by $43.0 mln over the past reporting period (2.7% of market cap)
- FCF (LTM) +$0.5 bln (positive), 32.4% of market cap
- EV/EBITDA multiple is 19.1x compared to historical level (75th percentile) of 19.4x
- EV/Sales multiple is 2.2x
The company showed EPS +$0.00 per share. At the opening of the session the share price went up +0.7% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #STE
[STERIS](https://eninvs.com/all.php?name=STE) (Medical equipment supplier) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=STE&q=2024 q1&id=780502)
(2024-05-08, After Market Close):
- Revenue +2.5% YoY (vs +14.8% in previous quarter and historical rate +22.2%)
- EBITDA -5.6% YoY (vs +61.5% in previous quarter and historical rate +34.2%)
- EBITDA margin 30.7% decreased compared to 33.3% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (0.0% of market cap)
- FCF (LTM) -$0.1 bln (negative), 0.6% of market cap
- EV/EBITDA multiple is 15.7x compared to historical level (75th percentile) of 28.8x
- EV/Sales multiple is 4.2x
The company showed EPS +$1.54 per share. At the opening of the session the share price went up +6.1% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #SONX
[Sonendo, Inc.](https://eninvs.com/all.php?name=SONX) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169041)
(2024-05-08, After Market Close):
- Revenue -36.4% YoY (vs -83.3% in previous quarter and historical rate -14.6%)
- EBITDA margin -142.9% decreased compared to -127.3% same period last year
- Net Debt decreased by $2.0 mln over the past reporting period (23.5% of market cap)
- FCF (LTM) -$0.0 bln (negative), 294.0% of market cap
- EV/Sales multiple is -0.0x
The company showed EPS -$0.07 per share. At the opening of the session the share price went up +7.3% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #SNEX
[StoneX Group](https://eninvs.com/all.php?name=SNEX) (Financial service provider) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=168957)
(2024-05-08, After Market Close):
- Revenue +36.8% YoY (vs +50.4% in previous quarter and historical rate +75.5%)
- Net Income +26.2% YoY (vs -10.4% in previous quarter and historical rate +37.4%)
- Net Income margin 0.2% has not changed compared to 0.3% same period last year
- P/E multiple is 9.5x compared to historical level (75th percentile) of 8.7x
- P/S multiple is 0.0x
- Price to book: 1.5x
The company showed EPS +$1.63 per share. At the opening of the session the share price went up +0.1% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #SMSI
[Smith Micro Software](https://eninvs.com/all.php?name=SMSI) (Software — Application) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=SMSI&q=2024 q1&id=780494)
(2024-05-08, After Market Close):
- Revenue -45.5% YoY (vs -18.2% in previous quarter and historical rate -7.6%)
- EBITDA margin -500.0% decreased compared to -45.5% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) +$0.0 bln (positive), 3.2% of market cap
- EV/Sales multiple is 5.2x
The company showed EPS -$3.28 per share
------------------------------------------------
2024-05-13
#reports #SBRA
[Sabra Health Care](https://eninvs.com/all.php?name=SBRA) (Real estate investment fund) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169056)
(2024-05-08, After Market Close):
- Revenue +3.7% YoY (vs -1.2% in previous quarter and historical rate +3.2%)
- EBITDA +3.7% YoY (vs -1.2% in previous quarter and historical rate +41.9%)
- EBITDA margin 100.0% has not changed compared to 100.0% same period last year
- EV/EBITDA multiple is 8.8x compared to historical level (75th percentile) of 19.7x
- EV/Sales multiple is 8.7x
The company showed EPS +$0.11 per share. At the opening of the session the share price went down -0.8% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #RGNX
[REGENXBIO](https://eninvs.com/all.php?name=RGNX) (Developer of viral gene therapy) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169091)
(2024-05-08, After Market Close):
- Revenue -15.8% YoY (vs -29.0% in previous quarter and historical rate +2.6%)
- EBITDA margin -375.0% decreased compared to -331.6% same period last year
- Net Debt decreased by $65.0 mln over the past reporting period (9.6% of market cap)
- FCF (LTM) +$0.0 bln (positive), 1.8% of market cap
- EV/Sales multiple is 4.9x
The company showed EPS -$1.38 per share. At the opening of the session the share price went down -0.7% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #RCUS
[Arcus Biosciences](https://eninvs.com/all.php?name=RCUS) (Medicines developer) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=RCUS&q=2024 q1&id=780470)
(2024-05-08, After Market Close):
- Revenue +480.0% YoY (vs -8.8% in previous quarter and historical rate +79.6%)
- EBITDA margin -9.7% increased compared to -336.0% same period last year
- Net Debt increased by $866.0 mln over the past reporting period (94.6% of market cap)
- FCF (LTM) -$0.2 bln (negative), 19.4% of market cap
- EV/Sales multiple is 0.2x
The company showed EPS -$0.05 per share. At the opening of the session the share price went up +11.1% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #QRTEB
[Qurate Retail](https://eninvs.com/all.php?name=QRTEB) (Internet Retail) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169026)
(2024-05-08, Before Market Open):
- Revenue -11.4% YoY (vs +140.5% in previous quarter and historical rate -1.9%)
- EBITDA -11.6% YoY (vs -100.7% in previous quarter and historical rate -4.0%)
- EBITDA margin 10.4% has not changed compared to 10.4% same period last year
- Net Debt increased by $166.0 mln over the past reporting period (28.3% of market cap)
- FCF (LTM) +$0.4 bln (positive), 71.5% of market cap
- EV/EBITDA multiple is 7.2x compared to historical level (75th percentile) of 6.2x
- EV/Sales multiple is 0.7x
The company showed EPS -$0.00 per share. At the opening of the session the share price went up +11.2% vs S&P500 -0.4%
------------------------------------------------
2024-05-13
#reports #PYCR
[Paycor HCM, Inc.](https://eninvs.com/all.php?name=PYCR) (Software — Application) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=168862)
(2024-05-08, After Market Close):
- Revenue +16.1% YoY (vs +20.3% in previous quarter and historical rate +25.0%)
- EBITDA +150.0% YoY (vs -1000.0% in previous quarter)
- EBITDA margin 5.3% increased compared to 2.5% same period last year
- Net Debt decreased by $29.0 mln over the past reporting period (1.1% of market cap)
- FCF (LTM) -$0.0 bln (negative), 0.7% of market cap
- EV/Sales multiple is 3.9x
The company showed EPS +$0.03 per share. At the opening of the session the share price went down -4.9% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #PSNL
[Personalis](https://eninvs.com/all.php?name=PSNL) (Diagnostics and Research) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169066)
(2024-05-08, After Market Close):
- Revenue +5.3% YoY (vs +17.6% in previous quarter and historical rate -0.2%)
- EBITDA margin -85.0% increased compared to -147.4% same period last year
- Net Debt increased by $13.0 mln over the past reporting period (16.7% of market cap)
- FCF (LTM) -$0.0 bln (negative), 55.2% of market cap
- EV/Sales multiple is 0.3x
The company showed EPS -$0.26 per share. At the opening of the session the share price went up +9.3% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #NPCE
[NeuroPace, Inc.](https://eninvs.com/all.php?name=NPCE) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169067)
(2024-05-08, After Market Close):
- Revenue +28.6% YoY (vs +38.5% in previous quarter and historical rate +21.5%)
- EBITDA margin -38.9% increased compared to -57.1% same period last year
- Net Debt increased by $8.0 mln over the past reporting period (3.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 1.4% of market cap
- EV/Sales multiple is 3.2x
The company showed EPS -$0.32 per share. At the opening of the session the share price went down -1.4% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #NL
[NL Industries](https://eninvs.com/all.php?name=NL) (Security and Protection Services) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169206)
(2024-05-08, After Market Close):
- Revenue -7.3% YoY (vs +7.5% in previous quarter and historical rate +11.8%)
- EBITDA -68.2% YoY (vs +10.5% in previous quarter and historical rate +35.3%)
- EBITDA margin 18.4% decreased compared to 53.7% same period last year
- Net Debt increased by $142.0 mln over the past reporting period (36.9% of market cap)
- FCF (LTM) +$0.0 bln (positive), 2.3% of market cap
- EV/EBITDA multiple is 4.0x compared to historical level (75th percentile) of 3.8x
- EV/Sales multiple is 1.5x
The company showed EPS +$0.14 per share. At the opening of the session the share price went down -0.3% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #MSEX
[Middlesex Water](https://eninvs.com/all.php?name=MSEX) (Water supply company) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169197)
(2024-05-08, After Market Close):
- Revenue +7.9% YoY (vs 0.0% in previous quarter and historical rate +6.1%)
- EBITDA +23.1% YoY (vs -11.8% in previous quarter and historical rate +8.3%)
- EBITDA margin 39.0% increased compared to 34.2% same period last year
- Net Debt increased by $377.0 mln over the past reporting period (36.7% of market cap)
- EV/EBITDA multiple is 20.7x compared to historical level (75th percentile) of 30.1x
- EV/Sales multiple is 8.3x
The company showed EPS +$0.60 per share. At the opening of the session the share price went up +3.6% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #MRVI
[Maravai LifeSciences Holdings, Inc.](https://eninvs.com/all.php?name=MRVI) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=MRVI&q=2024 q1&id=780423)
(2024-05-08, After Market Close):
- Revenue -19.0% YoY (vs -63.9% in previous quarter and historical rate +3.5%)
- EBITDA margin -139.1% decreased compared to -86.1% same period last year
- EV/Sales multiple is 5.0x
The company showed EPS -$0.09 per share. At the opening of the session the share price went up +3.2% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #MRUS
[Merus](https://eninvs.com/all.php?name=MRUS) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169112)
(2024-05-08, After Market Close):
- Revenue -38.5% YoY (vs -18.2% in previous quarter and historical rate +15.8%)
- EBITDA margin -575.0% decreased compared to -276.9% same period last year
- Net Debt increased by $17.0 mln over the past reporting period (0.7% of market cap)
- FCF (LTM) +$0.1 bln (positive), 4.0% of market cap
- EV/Sales multiple is 54.3x
The company showed EPS -$0.59 per share. At the opening of the session the share price went up +0.1% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #MRC
[MRC Global](https://eninvs.com/all.php?name=MRC) (Pipelines and components manufacturer) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=168725)
(2024-05-08, After Market Close):
- Revenue -8.9% YoY (vs -11.6% in previous quarter and historical rate +12.8%)
- EBITDA -28.4% YoY (vs -15.6% in previous quarter and historical rate +74.4%)
- EBITDA margin 6.0% decreased compared to 7.6% same period last year
- Net Debt decreased by $30.0 mln over the past reporting period (2.6% of market cap)
- FCF (LTM) +$0.2 bln (positive), 18.8% of market cap
- EV/EBITDA multiple is 9.0x compared to historical level (75th percentile) of 17.3x
- EV/Sales multiple is 0.6x
The company showed EPS +$0.22 per share. At the opening of the session the share price went up +4.9% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #MNKD
[MannKind Corporation](https://eninvs.com/all.php?name=MNKD) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169246)
(2024-05-08, After Market Close):
- Revenue +61.0% YoY (vs +61.1% in previous quarter and historical rate +65.6%)
- EBITDA margin 27.3% increased compared to -9.8% same period last year
- Net Debt decreased by $11.0 mln over the past reporting period (1.0% of market cap)
- FCF (LTM) +$0.1 bln (positive), 13.4% of market cap
- EV/EBITDA multiple is 29.7x compared to historical level (75th percentile) of 80.1x
- EV/Sales multiple is 4.7x
The company showed EPS +$0.03 per share. At the opening of the session the share price went up +3.4% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #LTRPB
[Liberty TripAdvisor](https://eninvs.com/all.php?name=LTRPB) (Internet Content and Information) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169098)
(2023-05-03):
- Revenue +6.5% YoY (vs +10.2% in previous quarter and historical rate +65.8%)
- EBITDA 0.0% YoY (vs +562.5% in previous quarter and historical rate +54.8%)
- EBITDA margin 1.0% has not changed compared to 1.1% same period last year
- Net Debt decreased by $98.0 mln over the past reporting period (223.4% of market cap)
- FCF (LTM) +$0.7 bln (positive), 1598.1% of market cap
- EV/Sales multiple is 1.1x
The company showed EPS -$0.85 per share
------------------------------------------------
2024-05-13
#reports #LBRDK
[Liberty Broadband (K)](https://eninvs.com/all.php?name=LBRDK) ( Multinational telecommunications company) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169102)
(2024-05-08, Before Market Open):
- Revenue -0.4% YoY (vs 0.0% in previous quarter and historical rate +49.7%)
- EBITDA +5.4% YoY (vs +117.6% in previous quarter and historical rate +69.4%)
- EBITDA margin 31.8% increased compared to 30.1% same period last year
- Net Debt decreased by $50.0 mln over the past reporting period (0.6% of market cap)
- FCF (LTM) +$0.1 bln (positive), 0.8% of market cap
- EV/EBITDA multiple is 41.1x compared to historical level (75th percentile) of 77.3x
- EV/Sales multiple is 12.7x
The company showed EPS +$1.69 per share. At the opening of the session the share price went down -0.5% vs S&P500 -0.4%
------------------------------------------------
2024-05-13
#reports #HUBS
[HubSpot](https://eninvs.com/all.php?name=HUBS) (Platform for marketing and sales) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=168524)
(2024-05-08, After Market Close):
- Revenue +22.9% YoY (vs +23.8% in previous quarter and historical rate +33.9%)
- EBITDA margin -1.3% increased compared to -5.6% same period last year
- Net Debt decreased by $145.0 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) -$0.1 bln (negative), 0.3% of market cap
- EV/Sales multiple is 12.2x
The company showed EPS +$0.12 per share. At the opening of the session the share price went up +5.9% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #HNST
[The Honest Company, Inc.](https://eninvs.com/all.php?name=HNST) (Specialty Retail) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=HNST&q=2024 q1&id=780369)
(2024-05-08, After Market Close):
- Revenue +3.6% YoY (vs +9.8% in previous quarter and historical rate +4.0%)
- EBITDA margin -1.2% increased compared to -21.7% same period last year
- Net Debt decreased by $3.0 mln over the past reporting period (1.0% of market cap)
- FCF (LTM) +$0.0 bln (positive), 9.9% of market cap
- EV/Sales multiple is 0.8x
The company showed EPS -$0.01 per share. At the opening of the session the share price went up +1.7% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #HCI
[HCI Group](https://eninvs.com/all.php?name=HCI) (Insurance services provider) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=168713)
(2024-05-08, After Market Close):
- Revenue +60.5% YoY (vs +35.8% in previous quarter and historical rate +27.4%)
- Net Income +216.7% YoY (vs +1266.7% in previous quarter and historical rate +46.3%)
- Net Income margin 27.5% increased compared to 14.0% same period last year
- P/E multiple is 7.3x compared to historical level (75th percentile) of 107.2x
- P/S multiple is 1.5x
- Price to book: 2.4x
The company showed EPS +$3.68 per share. At the opening of the session the share price went up +3.7% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #GMRE
[Global Medical REIT](https://eninvs.com/all.php?name=GMRE) (REIT — Healthcare Facilities) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169070)
(2024-05-07, After Market Close):
- Revenue -2.8% YoY (vs -8.3% in previous quarter and historical rate +12.8%)
- EBITDA -5.0% YoY (vs -9.5% in previous quarter and historical rate +24.8%)
- EBITDA margin 54.3% decreased compared to 55.6% same period last year
- EV/EBITDA multiple is 16.2x compared to historical level (75th percentile) of 23.6x
- EV/Sales multiple is 9.0x
The company showed EPS +$0.01 per share. At the opening of the session the share price went down -0.4% vs S&P500 -0.4%
------------------------------------------------
2024-05-13
#reports #GLP
[Global Partners LP](https://eninvs.com/all.php?name=GLP) (Oil and Gas Midstream) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169020)
(2024-05-08, Before Market Open):
- Revenue +2.9% YoY (vs -0.4% in previous quarter and historical rate +34.3%)
- EBITDA +7.4% YoY (vs -46.7% in previous quarter and historical rate +24.3%)
- EBITDA margin 1.4% has not changed compared to 1.3% same period last year
- Net Debt increased by $225.0 mln over the past reporting period (15.1% of market cap)
- FCF (LTM) -$0.0 bln (negative), 1.9% of market cap
- EV/EBITDA multiple is 9.5x compared to historical level (75th percentile) of 9.5x
- EV/Sales multiple is 0.2x
The company showed EPS -$0.26 per share. At the opening of the session the share price went down -9.4% vs S&P500 -0.4%
------------------------------------------------
2024-05-13
#reports #FRAF
[Franklin Financial Services Corporation](https://eninvs.com/all.php?name=FRAF) (Banks — Regional) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169207)
(2023-04-25, Before Market Open):
- Revenue +7.7% YoY (vs 0.0% in previous quarter and historical rate +8.9%)
- Net Income margin 21.4% increased compared to -7.7% same period last year
- P/E multiple is 7.2x compared to historical level (75th percentile) of 11.2x
- P/S multiple is 1.7x
- Price to book: 0.9x
The company showed EPS +$0.77 per share. At the opening of the session the share price went up +0.5% vs S&P500 -0.3%
------------------------------------------------
2024-05-13
#reports #FNA
[Paragon 28, Inc.](https://eninvs.com/all.php?name=FNA) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169069)
(2024-05-08, After Market Close):
- Revenue +17.3% YoY (vs +17.3% in previous quarter and historical rate +46.6%)
- EBITDA margin -14.8% decreased compared to -9.6% same period last year
- Net Debt increased by $17.0 mln over the past reporting period (2.7% of market cap)
- FCF (LTM) -$0.1 bln (negative), 14.9% of market cap
- EV/Sales multiple is 3.0x
The company showed EPS -$0.18 per share. At the opening of the session the share price went down -8.7% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #ESTA
[Establishment Labs](https://eninvs.com/all.php?name=ESTA) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=ESTA&q=2024 q1&id=780336)
(2024-05-08, After Market Close):
- Revenue -21.3% YoY (vs -27.3% in previous quarter and historical rate +30.4%)
- EBITDA margin -16.2% decreased compared to -10.6% same period last year
- Net Debt decreased by $29.0 mln over the past reporting period (2.0% of market cap)
- FCF (LTM) -$0.0 bln (negative), 0.8% of market cap
- EV/Sales multiple is 10.1x
The company showed EPS -$0.58 per share. At the opening of the session the share price went up +6.1% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #ENV
[Envestnet](https://eninvs.com/all.php?name=ENV) (Software for financial advisors creator) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169024)
(2024-05-07, After Market Close):
- Revenue -3.0% YoY (vs -43.0% in previous quarter and historical rate +2.7%)
- EBITDA +200.0% YoY (vs +16300.0% in previous quarter and historical rate +29.3%)
- EBITDA margin 22.8% increased compared to 7.4% same period last year
- Net Debt decreased by $905.0 mln over the past reporting period (24.6% of market cap)
- FCF (LTM) +$0.1 bln (positive), 2.5% of market cap
- EV/EBITDA multiple is 16.1x compared to historical level (75th percentile) of 64.9x
- EV/Sales multiple is 4.2x
The company showed EPS +$0.05 per share. At the opening of the session the share price went up +2.0% vs S&P500 -0.4%
------------------------------------------------
2024-05-13
#reports #EMKR
[EMCORE Corporation](https://eninvs.com/all.php?name=EMKR) (Semiconductors) reported for 2024 q1
(2024-05-02, After Market Close):
- Revenue -25.9% YoY (vs -4.0% in previous quarter and historical rate -1.3%)
- EBITDA margin -45.0% decreased compared to -40.7% same period last year
- Net Debt increased by $9.0 mln over the past reporting period (96.3% of market cap)
- FCF (LTM) +$0.0 bln (positive), 32.1% of market cap
- EV/Sales multiple is 0.3x
The company showed EPS -$0.95 per share. At the opening of the session the share price went up +1.6% vs S&P500 +1.2%
------------------------------------------------
2024-05-13
#reports #ECOR
[electroCore](https://eninvs.com/all.php?name=ECOR) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169080)
(2023-05-17, After Market Close):
- Revenue +66.7% YoY (vs +66.7% in previous quarter and historical rate +94.4%)
- EBITDA margin -80.0% increased compared to -200.0% same period last year
- Net Debt increased by $4.0 mln over the past reporting period (12.3% of market cap)
- FCF (LTM) -$0.0 bln (negative), 6.2% of market cap
- EV/Sales multiple is 1.4x
The company showed EPS -$0.53 per share. At the opening of the session the share price went up +0.1% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #DUOL
[Duolingo, Inc.](https://eninvs.com/all.php?name=DUOL) (Software — Application) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=DUOL&q=2024 q1&id=780322)
(2024-05-08, After Market Close):
- Revenue +44.8% YoY (vs +45.2% in previous quarter and historical rate +41.9%)
- EBITDA margin 11.3% increased compared to -6.0% same period last year
- Net Debt decreased by $49.0 mln over the past reporting period (0.7% of market cap)
- FCF (LTM) +$0.2 bln (positive), 2.1% of market cap
- EV/Sales multiple is 12.2x
The company showed EPS +$0.57 per share. At the opening of the session the share price went down -17.8% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #DDI
[DoubleDown Interactive Co., Ltd.](https://eninvs.com/all.php?name=DDI) (Electronic Gaming and Multimedia) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=DDI&q=2024 q1&id=780307)
(2024-05-08, After Market Close):
- Revenue +12.8% YoY (vs +9.2% in previous quarter and historical rate -5.4%)
- EBITDA +28.0% YoY (vs +3500.0% in previous quarter and historical rate +1.1%)
- EBITDA margin 36.4% increased compared to 32.1% same period last year
- Net Debt decreased by $266.0 mln over the past reporting period (42.9% of market cap)
- FCF (LTM) -$0.0 bln (negative), 5.0% of market cap
- EV/EBITDA multiple is 2.8x compared to historical level (75th percentile) of 5.4x
- EV/Sales multiple is 1.1x
The company showed EPS +$0.61 per share. At the opening of the session the share price went up +2.4% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #CTLT
[Catalent](https://eninvs.com/all.php?name=CTLT) (Medicines developer) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169094)
(2024-05-02, Before Market Open):
- Revenue +3.6% YoY (vs -10.2% in previous quarter and historical rate +4.7%)
- EBITDA margin 8.0% increased compared to -12.7% same period last year
- Net Debt increased by $68.0 mln over the past reporting period (0.7% of market cap)
- FCF (LTM) +$0.5 bln (positive), 5.2% of market cap
- EV/Sales multiple is 2.4x
The company showed EPS -$0.55 per share. At the opening of the session the share price went up +0.6% vs S&P500 +0.6%
------------------------------------------------
2024-05-13
#reports #CTKB
[Cytek Biosciences, Inc.](https://eninvs.com/all.php?name=CTKB) (Medical Devices) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169155)
(2024-05-08, After Market Close):
- Revenue +21.6% YoY (vs +22.9% in previous quarter and historical rate +20.8%)
- EBITDA margin -20.0% increased compared to -29.7% same period last year
- Net Debt decreased by $1.5 bln over the past reporting period (180.5% of market cap)
- FCF (LTM) -$0.0 bln (negative), 3.0% of market cap
- EV/Sales multiple is 2.9x
The company showed EPS -$0.05 per share. At the opening of the session the share price went up +1.3% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #CR
[Crane](https://eninvs.com/all.php?name=CR) (Engineering industrial products manufacturer) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169183)
(2024-04-22, After Market Close):
- Revenue -4.6% YoY (vs -56.7% in previous quarter and historical rate -15.8%)
- EBITDA -16.0% YoY (vs -0.6% in previous quarter and historical rate +3.5%)
- EBITDA margin 25.2% decreased compared to 28.6% same period last year
- Net Debt decreased by $386.0 mln over the past reporting period (4.8% of market cap)
- FCF (LTM) +$0.6 bln (positive), 6.9% of market cap
- EV/EBITDA multiple is 20.2x compared to historical level (75th percentile) of 16.4x
- EV/Sales multiple is 5.9x
The company showed EPS +$1.12 per share. At the opening of the session the share price went up +3.9% vs S&P500 +0.4%
------------------------------------------------
2024-05-13
#reports #CPRX
[Catalyst Pharmaceuticals](https://eninvs.com/all.php?name=CPRX) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169030)
(2024-05-08, After Market Close):
- Revenue +16.5% YoY (vs +82.0% in previous quarter and historical rate +54.7%)
- EBITDA -22.9% YoY (vs +35.5% in previous quarter and historical rate +41.1%)
- EBITDA margin 27.3% decreased compared to 41.2% same period last year
- Net Debt decreased by $173.0 mln over the past reporting period (10.2% of market cap)
- FCF (LTM) +$0.2 bln (positive), 9.1% of market cap
- EV/EBITDA multiple is 17.8x compared to historical level (75th percentile) of 16.6x
- EV/Sales multiple is 3.4x
The company showed EPS +$0.19 per share. At the opening of the session the share price went up +1.0% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #CPK
[Chesapeake Utilities Corporation](https://eninvs.com/all.php?name=CPK) (Utilities — Regulated Gas) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169179)
(2024-05-08, After Market Close):
- Revenue +12.8% YoY (vs -1.1% in previous quarter and historical rate +10.5%)
- EBITDA +34.7% YoY (vs +32.6% in previous quarter and historical rate +11.6%)
- EBITDA margin 39.4% increased compared to 33.0% same period last year
- Net Debt decreased by $4.0 mln over the past reporting period (0.2% of market cap)
- FCF (LTM) -$0.6 bln (negative), 27.4% of market cap
- EV/EBITDA multiple is 14.6x compared to historical level (75th percentile) of 15.6x
- EV/Sales multiple is 5.2x
The company showed EPS +$2.07 per share. At the opening of the session the share price went down -0.7% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #COOK
[Traeger, Inc.](https://eninvs.com/all.php?name=COOK) (Furnishings, Fixtures and Appliances) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=COOK&q=2024 q1&id=780295)
(2024-05-08, After Market Close):
- Revenue -5.2% YoY (vs +18.1% in previous quarter and historical rate -5.1%)
- Net Debt increased by $18.0 mln over the past reporting period (6.2% of market cap)
- FCF (LTM) +$0.0 bln (positive), 10.3% of market cap
- EV/Sales multiple is 1.2x
The company showed EPS -$0.04 per share. At the opening of the session the share price went down -0.4% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #CDXC
[ChromaDex Corporation](https://eninvs.com/all.php?name=CDXC) (Biotechnology) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=CDXC&q=2024 q1&id=780288)
(2024-05-08, After Market Close):
- Revenue -4.3% YoY (vs 0.0% in previous quarter and historical rate +12.8%)
- EV/Sales multiple is 3.2x
The company showed EPS -$0.01 per share. At the opening of the session the share price went down -5.7% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #CDLX
[Cardlytics](https://eninvs.com/all.php?name=CDLX) (Marketing services provider ) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169114)
(2024-03-14, After Market Close):
- Revenue +6.3% YoY (vs +7.2% in previous quarter and historical rate +22.1%)
- EBITDA -189.5% YoY (vs -9700.0% in previous quarter and historical rate -1.9%)
- EBITDA margin -25.0% decreased compared to 29.7% same period last year
- Net Debt decreased by $174.0 mln over the past reporting period (50.1% of market cap)
- FCF (LTM) -$0.0 bln (negative), 13.5% of market cap
- EV/Sales multiple is 1.7x
The company showed EPS -$0.56 per share. At the opening of the session the share price went up +52.7% vs S&P500 -0.5%
------------------------------------------------
2024-05-13
#reports #CAKE
[Cheesecake Factory](https://eninvs.com/all.php?name=CAKE) (Restaurants) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=169242)
(2024-05-08, After Market Close):
- Revenue +2.9% YoY (vs -1.8% in previous quarter and historical rate +26.6%)
- EBITDA +68.4% YoY (vs +300.0% in previous quarter and historical rate +46.9%)
- EBITDA margin 10.8% increased compared to 6.6% same period last year
- Net Debt increased by $1.8 bln over the past reporting period (100.0% of market cap)
- EV/EBITDA multiple is 15.2x compared to historical level (75th percentile) of 14.8x
- EV/Sales multiple is 1.0x
The company showed EPS +$0.68 per share. At the opening of the session the share price went up +7.4% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #BYND
[Beyond Meat](https://eninvs.com/all.php?name=BYND) (Food products provider) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=BYND&q=2024 q1&id=780283)
(2024-05-08, After Market Close):
- Revenue -17.4% YoY (vs -7.5% in previous quarter and historical rate -6.7%)
- EBITDA margin -61.8% decreased compared to -56.5% same period last year
- Net Debt increased by $37.0 mln over the past reporting period (8.0% of market cap)
- FCF (LTM) -$0.1 bln (negative), 30.3% of market cap
- EV/Sales multiple is 4.7x
The company showed EPS -$0.84 per share. At the opening of the session the share price went down -14.4% vs S&P500 0.0%
------------------------------------------------
2024-05-13
#reports #BLZE
[Backblaze, Inc.](https://eninvs.com/all.php?name=BLZE) (Software — Infrastructure) reported for [2024 q1](https://eninvs.com/press_release.php?ticker=BLZE&q=2024 q1&id=780279)
(2024-05-08, After Market Close):
- Revenue +30.4% YoY (vs +26.1% in previous quarter and historical rate +23.0%)
- EBITDA margin -13.3% increased compared to -47.8% same period last year
- Net Debt decreased by $2.0 mln over the past reporting period (0.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 7.9% of market cap
- EV/Sales multiple is 2.3x
The company showed EPS -$0.27 per share. At the opening of the session the share price went down -9.2% vs S&P500 0.0%
